Wed, Apr 30, 10:09 AM (12 days ago)
**Summary of INVO Fertility, Inc. (IVF) 2024 Annual Report** **Financial Performance:** - **Revenue:** $6.5 million (2024) vs. $3.0 million (2023) - **Net Loss:** $9.1 million (2024) vs. $8.0 million (2023) - **Adjusted EBITDA:** Improved significantly due to Wisconsin Fertility Institute (WFI) performance. - **Cash Flow:** $0.7 million (2024) vs. $0.2 million (2023) **Operating Expenses:** - **Cost of Revenue:** $3.7 million (2024) vs. $1.9 million (2023) - **Selling, General, and Administrative Expenses:** $9.1 million (2024) vs. $7.5 million (2023) - **Research and Development Expenses:** $0.5 million (2024) vs. $0.2 million (2023) **Earnings per Share:** - **Basic and Diluted Loss per Share:** $30.19 (2024) vs. $67.37 (2023) **Strategic Overview:** - **Fertility Clinics:** Focus on acquiring and operating profitable IVF clinics and INVO Centers. - **INVOcell Device:** Proprietary technology for intravaginal culture (IVC) procedure. - **NAYA Therapeutics:** Acquired in 2024, but divesting majority stake to refocus on fertility market. **Future Outlook:** - **Growth Strategy:** Continue acquiring IVF clinics and opening INVO Centers. - **Market Opportunity:** Large, underserved global ART market with increasing demand. - **Financial Condition:** Dependent on raising additional capital; negative working capital and stockholders' equity. **Risk Factors:** - **Financial Risks:** Significant operating losses, dependence on raising capital. - **Operational Risks:** Dependence on key personnel, regulatory risks, competition. - **Market Risks:** Volatility in stock price, dependence on fertility market trends. **Market Position Changes:** - **Name Change:** From NAYA Biosciences, Inc. to INVO Fertility, Inc. - **Ticker Symbol Change:** From NAYA to IVF. - **Reverse Stock Split:** 1-for-12 reverse stock split effective March 18, 2025. **Note:** Amounts are usually in thousands, 000s.